PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
16
09
2024
accepted:
19
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
The current study was inspired by observations from exploratory analyses of an institutional cohort with chronic myelomonocytic leukemia (CMML; N = 398) that revealed no instances of blast transformation in the seven patients with plant homeodomain finger protein 6 (PHF6) mutation (PHF6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Références
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200‐1228.
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142‐1165.
Coltro G, Mangaonkar AA, Lasho TL, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)‐a study of 1084 patients. Leukemia. 2020;34:1407‐1421.
Patnaik MM, Barraco D, Lasho TL, et al. DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92:56‐61.
Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428‐2436.
Elena C, Galli A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408‐1417.
Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two‐center study of 466 patients. Leukemia. 2014;28:2206‐2212.
Damm F, Itzykson R, Kosmider O, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013;27:1401‐1403.
Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia. 2013;27:2100‐2102.
Patnaik MM, Wassie EA, Padron E, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015;5:e270.
Cui Y, Tong H, Du X, et al. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol. 2015;4:14.
Csizmar CM, Gurney M, Kanagal‐Shamanna R, et al. ASXL1/TET2 genotype‐based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024. doi:10.3324/haematol.2024.285410
Gurney M, Greipp PT, Gliem T, et al. TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia. Leuk Res. 2023;134:107391.
Zhao W, Zhang C, Li Y, et al. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta‐analysis. Hematology. 2022;27:367‐378.
Patnaik MM, Zahid MF, Lasho TL, et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016;6:e472.
Liu Z, Li F, Ruan K, et al. Structural and functional insights into the human Borjeson‐Forssman‐Lehmann syndrome‐associated protein PHF6. J Biol Chem. 2014;289:10069‐10083.
McRae HM, Garnham AL, Hu Y, et al. PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia. Blood. 2019;133:1729‐1741.
Eisa YA, Guo Y, Yang FC. The role of PHF6 in hematopoiesis and hematologic malignancies. Stem Cell Rev Rep. 2023;19:67‐75.
Jalnapurkar SS, Pawar AS, George SS, et al. PHF6 suppresses self‐renewal of leukemic stem cells in AML. Leukemia. 2024;38:1938‐1948.
Yuan S, Gao M, Wang Y, et al. PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model. Cancer Cell Int. 2024;24:66.
Lower KM, Turner G, Kerr BA, et al. Mutations in PHF6 are associated with Borjeson‐Forssman‐Lehmann syndrome. Nat Genet. 2002;32:661‐665.
Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T‐cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338‐342.
Van Vlierberghe P, Patel J, Abdel‐Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25:130‐134.
Mori T, Nagata Y, Makishima H, et al. Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia. 2016;30:2270‐2273.
Bataller A, Chien KS, Sasaki K, et al. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res. 2023;127:107044.
Li X, Yao H, Chen Z, Wang Q, Zhao Y, Chen S. Somatic mutations of PHF6 in patients with chronic myeloid leukemia in blast crisis. Leuk Lymphoma. 2013;54:671‐672.
Kubota Y, Gu X, Terkawi L, et al. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting. Nat Commun. 2024;15:1832.
Kurzer JH, Weinberg OK. PHF6 mutations in hematologic malignancies. Front Oncol. 2021;11:704471.
Desai P, Mencia‐Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24:1015‐1023.
Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079‐1089.
Meacham CE, Lawton LN, Soto‐Feliciano YM, et al. A genome‐scale in vivo loss‐of‐function screen identifies Phf6 as a lineage‐specific regulator of leukemia cell growth. Genes Dev. 2015;29:483‐488.